Detangle: The Electric Comb That Regrew Nearly All Hair — in Mice

An experimental electric comb built by engineers at Beihang University in Beijing regrew nearly 100% of the hair on bald patches in mice — in just one month. The device, called Detangle, was described in Nature Communications on 3 November 2026. Its teeth carry tiny electrodes and small pods of medicine, and each stroke creates an electric field reaching about nine times deeper into the follicles than electrodes placed on the skin. The mice were combed once every three days; after 28 days, the treated patches had regrown nearly all of their hair, beating daily minoxidil, which reached roughly 70%. And here is the sentence that matters most: every result so far comes from mice whose baldness was induced in the lab. No human has used it yet, and nobody is selling it. This is promising science — not a cure you can buy.

What Detangle is

Detangle is not a shampoo, a serum or a pill. It is a piece of hardware: a comb-shaped bioelectronic system developed by a team led by researchers at Beihang University in Beijing, from the School of Engineering Medicine and the School of Biological Science and Medical Engineering, with collaborators from hospitals and universities across China and Hong Kong. The paper's lead authors are Feng Liu, Fuqi Yao and Hong Sun, and the work was published in Nature Communications on 3 November 2026 (received 28 January 2026, accepted 13 October 2026). The name is a nod to Disney's 2010 film Tangled.

From the outside, Detangle looks like an ordinary comb. The difference is in its teeth. They come in two lengths, set at different heights, and they carry two things an ordinary comb never has: tiny electrodes, and little reservoirs of medicine that dispense their contents through a mechanism the researchers describe as working like a ballpoint pen. It is used the way you use any comb — drawn through the hair, once every three days — while it does two jobs at once: stimulating the follicles with electricity, and delivering treatment deep into them.

The condition it targets is androgenetic alopecia, better known as pattern baldness: the slow, progressive thinning that recedes at the temples and crown in men and thins across the parting in women. It is the most common form of hair loss in the world, affecting more than 1.5 billion people. Detangle deserves attention because the science behind it is genuinely clever — and scepticism because, for now, it has only ever been tested on mice.

How it works, step by step

Detangle works in three linked stages, and the clever part is that they happen in a single stroke of the comb. Understanding each stage is the key to understanding why the researchers think this approach could succeed where creams and pills struggle.

Step 1 — The teeth lift the skin

The comb's teeth are not all the same length. They are set at two different heights, so as the comb moves through the hair, the longer teeth and the shorter teeth work together to gently raise and furrow the skin. That small mechanical action matters: it brings the electrodes into close, even contact with the scalp and shapes the skin so the electric field that follows is concentrated where it is needed — around the hair follicles, which sit deep below the surface.

Step 2 — The electric field goes deep

Each tooth carries a tiny electrode, and as the comb moves, those electrodes deliver small pulses of electricity. Because the electrodes sit at different heights, the field they create reaches down into the follicle region: the paper reports it penetrates up to about nine times deeper into hair follicle regions than electrodes simply placed on the skin. That depth is the whole point — follicles are buried in the skin, and most treatments never really reach them.

The electric field does two things. First, it gently stimulates the follicles themselves — electrostimulation, a technique already used in other areas of medicine to nudge cells into activity. Second, it briefly opens up the follicle cells, a process called electroporation: tiny, temporary pores form in the cell membranes, letting molecules slip inside that would otherwise be locked out. The pulses are small and the effect is brief, and the researchers describe the approach as safe and non-invasive in the animals they tested.

Step 3 — Two medicines, delivered to the follicle

While the field is doing its work, the comb's reservoirs release two treatments directly into the follicle in the same stroke — the paper calls this "synchronizing" stimulation and delivery. The two treatments attack the problem from opposite directions:

Treatment one: a VEGF-A gene. The comb delivers a plasmid — a small loop of DNA — carrying the gene for vascular endothelial growth factor A (VEGF-A), a protein that tells the body to build new blood vessels. A growing hair needs a rich blood supply, and one reason shrinking follicles fail is that their blood supply withers with them. By switching on VEGF-A production inside the follicle cells, Detangle aims to regrow the tiny blood vessels that feed the hair, a process called angiogenesis.

Treatment two: an siRNA that silences DHT production. The second cargo is a small interfering RNA (siRNA) that targets SRD5A2, the gene for steroid 5-alpha-reductase type 2 — the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is the hormone that shrinks follicles in pattern baldness: in people who are genetically sensitive to it, DHT binds to follicle receptors and progressively miniaturises the follicle, so each new hair grows thinner and shorter until the follicle stops producing visible hair at all. The siRNA switches off the enzyme that makes DHT, cutting off the attack at its source. Detangle's bet is that doing it locally, inside the follicle, gets the benefit without the body-wide cost.

Put together, the logic is elegant: open the follicle cells with electricity, then deliver one treatment that feeds the follicle and one that stops the hormone attacking it — two mechanisms that reinforce each other.

The experiment and the numbers

The test was done on mice with lab-induced androgenetic alopecia: their backs were shaved and they were dosed with testosterone for 28 days. The Detangle group was combed once every three days. A comparison group received conventional topical minoxidil every day — the standard over-the-counter treatment, the active ingredient in Rogaine.

By day 28, the difference was striking. The mice treated with Detangle had regrown nearly 100% of the hair on the shaved area. The minoxidil group reached roughly 70%. The paper reports the improvement as going from about 70% to nearly 100% within one month, and the researchers concluded that electrostimulation via the Detangle system promotes hair growth and follicle regeneration "in a safe and effective manner" — a claim they make about the mice in their study, and only about the mice in their study.

Two things are worth noting. First, the comparison is fair: minoxidil is the treatment most people actually use, and beating it by roughly thirty percentage points is a real result. Second, the dosing schedule matters: Detangle was used once every three days, while minoxidil needs daily application — and a three-day rhythm is far easier to stick with than a daily ritual.

The researchers also report signs of safety in the animals, describing the system as safe and effective for deep tissue delivery in dermatology, and the pulses as gentle enough to count as non-invasive. That is encouraging — but it is safety in mice, on shaved backs, over a month. It says nothing yet about years of use on a human scalp.

Why creams and pills struggle — the problem Detangle is trying to solve

To understand why a comb is interesting at all, it helps to see why today's treatments disappoint so many people. Pattern baldness is, at its root, a delivery problem as much as a chemistry problem: the follicle is deep, the skin is designed to keep things out, and the drugs that work are hard to put exactly where they are needed.

Minoxidil is the treatment most people try first, and for good reason: it is available without a prescription, it is cheap, and it genuinely helps many people. But creams face a physical problem: the scalp's outer layer is built to keep the outside world out, and the follicle sits below it, so a large share of every application never reaches it. The result is uneven: some people respond well, others see almost nothing, and nobody can predict in advance which group they fall into. It also demands daily use, and the moment you stop, the gains unwind.

The DHT-blocking pills — finasteride and dutasteride — attack the hormonal cause, and they are the most effective drug treatments available. Their problem is the opposite of minoxidil's: swallowed as a pill, they lower DHT throughout the whole body, not just at the scalp. For some men that brings side effects that are hard to live with, including sexual side effects and mood changes, and the drugs must be taken indefinitely — stop, and the hair loss resumes. That trade-off is why many people who could benefit never start, or start and quit.

Transplants work, but they are surgery: expensive, limited by how much donor hair you have, and they do nothing to stop the remaining hair from thinning further.

Detangle's pitch is that it sidesteps both problems at once. Like a cream, it acts locally, on the scalp — so no body-wide hormone changes. Unlike a cream, it does not rely on passive absorption: the electric field opens the follicle cells and drives the treatment in, nine times deeper than a surface electrode. And because it is a comb, it folds into a habit people already have, once every three days. If it works in humans the way it worked in mice, that combination — local, deep, infrequent — is exactly what current treatments lack.

What the viral post gets right — and where it stops

Right: the device exists, the paper is real, and the numbers are real. Detangle is a genuine device from a real university team, published in a major peer-reviewed journal, Nature Communications, on 3 November 2026. The nine-times-deeper field, the two treatments, the once-every-three-days schedule and the nearly-100% regrowth figure all come from the paper itself, not from a press release or a social media account. The comparison with minoxidil — about 70% regrowth — is also from the paper.

Right: the mechanism is as clever as it sounds. Height-differentiated electrodes, ballpoint-style medicine reservoirs, a field that reaches the follicle, a blood-vessel-building gene and a DHT-silencing molecule delivered in the same stroke — that is all in the published work.

Stops short: mice are not people. Every result comes from mice whose baldness was induced in the lab with testosterone, on shaved backs, over 28 days. Human scalps are thicker than mouse skin, human hair grows on a different cycle, and human hormones are regulated differently. Treatments that cure baldness in mice have a long history of failing in humans. The paper's authors do not claim otherwise.

Stops short: there is no product. Detangle is a laboratory prototype. There is no price, no release date, no company selling it, no waiting list and no clinic offering it. The viral image of a hand holding a sleek transparent comb is a research device photographed for a paper, not a product shot. Anyone selling you a "Detangle comb" today is selling you something else.

Stops short: "nearly 100%" is a patch, not a head of hair. The figure refers to hair regrowth on the treated shaved patch of a mouse's back — a controlled area, under controlled conditions. It does not mean a bald person would regrow a full head of hair, and it does not mean the regrown hair would be thick, permanent or cosmetically the same as the hair that was lost. Regrowth coverage and regrowth quality are different things, and the paper measures the first far more than the second.

Stops short: one month is not a lifetime. The experiment ran for 28 days. Nobody knows whether the regrown hair stays, whether the follicles need repeated treatment forever, or whether the gene and siRNA treatments keep working on the fiftieth combing the way they worked on the first. Durability is usually the question that decides whether a hair treatment is a breakthrough or a footnote.

What has to happen before humans

For Detangle to become something a person could actually use, a long road lies between this paper and a bathroom shelf — and it is worth knowing what that road looks like, because it sets the timescale honestly.

First, bigger and longer animal studies. The mouse study is a proof of concept. The next step is larger animal studies over longer periods, checking not just whether hair grows but whether it stays, whether repeated gene and siRNA delivery causes irritation or an immune response, and whether months of electrical stimulation stay safe. Human skin is thicker than mouse skin, so the field strength and tooth design would need re-tuning for a human scalp — the "nine times deeper" figure was measured in mice and may not translate directly.

Then, human safety trials. Before any test of whether it works in people, regulators require tests of whether it is safe in people: small phase 1 trials on healthy volunteers, watching for skin irritation, pain, allergic reactions and unexpected effects from the gene and siRNA cargo. Gene and RNA therapy delivered through the skin faces particularly careful scrutiny — appropriate, and slow.

Then, efficacy trials. Only after safety comes the real question: does it regrow hair on human heads, in real pattern baldness, over months and years? Those trials need hundreds of volunteers, a placebo or minoxidil comparison group, and follow-up measured in years, not weeks. Hair grows about a centimetre a month, so even a successful trial takes a long time to read out.

Then, manufacturing and approval. A laboratory prototype has to become a manufacturable product — reservoirs refilled reliably, electrodes consistent, dose controlled — and then approved as a medical device, or as a drug-device combination, which is a harder path. Each step takes years and costs money, and most ideas do not survive all of them.

None of that means Detangle will fail. The mechanism is sound, the results are strong, and the problem it addresses — delivery to the follicle — is exactly the problem that has limited every treatment before it. But the honest timeline is years, not months. The right response to this paper is excitement, restrained by patience.

Frequently asked questions

Has the Detangle comb been tested on humans?

No. Every result published so far comes from mice with lab-induced pattern baldness. No human trial has been announced. Human scalps and hormones may respond differently, and human tolerability, lasting benefit and the demands of repeated treatment are all still open questions.

Can I buy a Detangle comb?

No. Detangle is a laboratory prototype from Beihang University, not a product. There is no price, no release date and no seller. Any product advertised online as the Detangle comb is not the device from this paper.

How is it different from minoxidil?

Minoxidil is a cream or foam applied to the scalp, and much of it never reaches the follicle — it relies on passive absorption through the skin, needs daily use, and works well for some people and barely for others. Detangle uses an electric field to open follicle cells and drive two treatments directly into them, and in the mouse study it was used once every three days. In that study it reached nearly 100% regrowth against about 70% for daily minoxidil — in mice.

What exactly does the comb deliver into the follicle?

Two things: a plasmid carrying the gene for VEGF-A, a growth factor that builds new blood vessels to feed the follicle, and an siRNA molecule that silences SRD5A2, the enzyme that makes DHT — the hormone that shrinks follicles in pattern baldness. The electric field both stimulates the follicle and briefly opens its cells so the two treatments can get inside.

Why "nine times deeper"?

Because the comb's electrodes sit at different heights on teeth of two lengths, the electric field they create reaches down into the follicle region instead of sitting on the skin's surface. The paper reports the field penetrates up to about nine times deeper into hair follicle regions than conventional external application of electrodes on the skin. That depth figure was measured in the mouse model.

Does this mean a cure for baldness is coming?

Not yet — and possibly never, from this device. Detangle is a strong proof of concept with striking mouse results, but the history of hair-loss research is full of mouse breakthroughs that did not survive human trials. The honest summary: a genuinely promising idea, years away from knowing whether it works in people.

Sources

• Nature Communications — Liu, F., Yao, F., Sun, H. et al. "Combing-triggered electrostimulation synchronizing deep delivery for rapid hair regrowth in androgenetic alopecia" (published 3 November 2026)
• DOI: 10.1038/s41467-026-79122-3
• Gizmodo — "An Experimental Electric Comb Just Beat Rogaine in Early Hair Loss Tests" (10 November 2026)
• Medical Xpress — "Could this experimental electric comb be a cure for baldness?" (November 2026)
• New Atlas — "Electric comb could give thinning hair a chance to bounce back" (11 November 2026)